rs2653349 — HCRTR2 Ile308Val

HCRTR2 Ile308Val — Sleepiness, Napping, and an Orexin Drug Target

The orexin system is your brain's primary wakefulness engine. Two neuropeptides — orexin A and orexin B — are released by a small cluster of hypothalamic neurons and broadcast across the brainstem to maintain alert wakefulness. They bind two receptors: HCRTR1 (orexin receptor 1) and HCRTR2 (orexin receptor 2)¹¹ HCRTR2 (orexin receptor 2)
the protein encoded by this gene, expressed in histaminergic, noradrenergic, and serotonergic nuclei that sustain wakefulness throughout the day. HCRTR2 is also the direct molecular target of the FDA-approved sleep medications suvorexant (Belsomra) and lemborexant (Dayvigo), which work by blocking it to allow sleep onset. This makes rs2653349 unusual: it sits within the drug target itself, meaning your genotype here directly describes the protein that sleep medications act on.

rs2653349 causes a missense change at codon 308 of HCRTR2 (NM_001526.5:c.922A>G, p.Ile308Val). The common G allele encodes valine (Val308), which is the functional wild-type at this position. The minor A allele encodes isoleucine (Ile308). Globally, about 81% of people carry two G alleles (Val308Val homozygous) and only about 4% carry two A alleles (Ile308Ile homozygous). The A allele is more common in European populations (~21%) than in East Asian ones (~5%).

The Mechanism

Codon 308 in HCRTR2 sits within the transmembrane domain of the receptor protein — the region that spans the cell membrane and is central to ligand binding and signal transduction. Substituting valine for isoleucine at this position alters the hydrophobic packing of the transmembrane helix, and homologous substitutions in canine HCRTR2 disrupt receptor signalling and produce narcolepsy²² homologous substitutions in canine HCRTR2 disrupt receptor signalling and produce narcolepsy
the narcoleptic Doberman mutation in HCRTR2 is a reference model for orexin receptor dysfunction. The human Ile308 (A allele) variant is thought to modestly reduce receptor signalling efficiency, attenuating the wake-promoting output of the orexin system.

The consequence is a quantitative shift toward increased sleepiness and daytime napping tendency rather than the catastrophic narcolepsy seen with complete receptor loss. The effect is additive: each A allele adds a small decrement to orexin-driven wakefulness.

The Evidence

The primary evidence comes from Dashti et al. 2021³³ Dashti et al. 2021
Genetic determinants of daytime napping and effects on cardiometabolic health. Nature Communications, a genome-wide association study of daytime napping in 993,966 individuals (UK Biobank discovery, 23andMe replication). The A allele at rs2653349 reached p = 6×10⁻⁵² for more frequent napping — among the most significant of 123 identified loci. Colocalization analysis confirmed that the same variant drives associations across napping frequency, evening chronotype, and reduced ease of awakening, identifying rs2653349 as a shared causal missense variant influencing multiple dimensions of sleep-wake regulation.

Jones et al. 2019⁴⁴ Jones et al. 2019
Genome-wide association analyses of chronotype in 697,828 individuals. Nature Communications independently found the A allele associated with evening chronotype (OR 1.068, p = 3×10⁻⁴⁸), consistent with reduced orexin morning wake drive. Mendelian randomisation in that dataset demonstrated that morning preference causally reduces schizophrenia risk (OR 0.89) and improves subjective well-being — consequences that flow indirectly from orexin receptor function.

A Japanese replication study (Miyagawa et al. 2022⁵⁵ Miyagawa et al. 2022
Journal of Human Genetics, n = 14,329) found nominally significant association between Ile308Val and daytime sleepiness (p = 0.044), providing cross-ancestry corroboration.

On the pharmacogenomics side, Firouzabadi et al. 2020⁶⁶ Firouzabadi et al. 2020
Neuropsychiatric Disease and Treatment found that GG homozygotes (Val308Val) — the common, wake-biased genotype — had 2.5-fold higher odds of developing insomnia during sertraline treatment for depression (OR 2.5, 95% CI 1.1–5.7, n = 96 MDD patients). This is a small study requiring replication, but the direction is biologically coherent: a more active orexin receptor may resist the sleep-disrupting side effects of serotonin reuptake inhibitors via arousal-system feedback.

Nishizawa et al. 2015⁷⁷ Nishizawa et al. 2015
Molecular Brain identified rs2653349 as the top hit in a GWAS of Fagerström nicotine dependence scores in a Japanese cohort, with the A allele associated with higher dependence (p = 0.0006). Orexin signalling is involved in addiction circuits, particularly craving and reward salience — suggesting that reduced HCRTR2 activity from Ile308 may modulate addictive behaviour alongside its sleep effects.

Practical Actions

For A allele carriers: a slightly reduced orexin wake drive means afternoon sleepiness and napping are partly constitutional, not just a lifestyle choice. Light-anchoring strategies and consistent sleep timing are especially important to prevent accumulating sleep pressure from fragmenting into chronic napping patterns.

For GG individuals: the stronger Val308 orexin signal maintains robust wakefulness but the Firouzabadi data suggests monitoring for sleep disruption if prescribed serotonergic antidepressants. GG individuals also need to know that suvorexant and lemborexant — which block Val308 receptors that are operating at full efficiency — may require careful dose titration.

Interactions

rs2653349 is one of three characterised functional variants in HCRTR2 in the GeneOps database. rs35833281 is an intronic chronotype tag SNP; rs1154155 is separately studied in narcolepsy and cluster headache literature. These variants may tag independent effects at the same locus or be in partial LD with rs2653349.

The orexin system interacts with the dopamine reward circuit (relevant to the nicotine dependence finding), with histaminergic arousal centres (where HCRTR2 drives the histamine wake signal), and with serotonergic nuclei (explaining the sertraline-insomnia pharmacogenomics finding). Variants in histamine pathway genes (e.g., HDC, HRH1) could compound the HCRTR2 sleepiness effect.